Daito Pharmaceutical Co.,Ltd.
4577.T
Get informed when a big investor buys or sells
+ FollowMarket Cap$37.88B
Close$
Share Statistics
| Market cap | $37.88 Billion |
|---|---|
| Enterprise Value | $46.22 Billion |
| Dividend Yield | $40.00 (3.03%) |
| Earnings per Share | $107.46 |
| Beta | 0.2 |
| Outstanding Shares | 28,894,000 |
Return
| Return on Equity | 5.98% |
|---|---|
| Return on Assets | 4.31% |
| Return on Invested Capital | 7.17% |
Valuation & Multiples
| P/E Ratio | 12.27 |
|---|---|
| PEG | 41.96 |
| Price to Sales | 0.75 |
| Price to Book Ratio | 0.72 |
| Enterprise Value to Revenue | 0.91 |
| Enterprise Value to EBIT | 10.88 |
| Enterprise Value to Net Income | 14 |
| Total Debt to Enterprise | 0.2 |
| Debt to Equity | 0.18 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 10, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$14.27 B
Average shareholder expectationNext Earnings Call
Expected Date
October 14, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$13.95 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Daito Pharmaceutical Co.,Ltd.
1,085 employees
CEO: Hiroshi Matsumori Daito Pharmaceutical Co.,Ltd. is a global entity primarily involved in the creation and sale of a diverse range of pharmaceutical products. Their offerings span active pharmaceutical ingredients (APIs) and chemical intermediates, alongsi...